Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Sarcopenia 1Prediabetic State 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Peripheral Nervous System Diseases 1Myelodysplastic Syndromes 1Leukemia, Myeloid 1Hematologic Neoplasms 1Heart Failure 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Cardiotoxicity 1Breast Neoplasms 1Anemia, Aplastic 1

Interventions

Acupuncture Therapy 10Exercise 6Cryotherapy 6Paclitaxel 5Glutamine 4Surveys and Questionnaires 3Duloxetine Hydrochloride 3Dexamethasone 3Bortezomib 3Acetylcysteine 3Thioctic Acid 2Tablets 2Sodium Chloride 2Saline Solution 2Physical Therapy Modalities 2Low-Level Light Therapy 2Fish Oils 2Fatty Acids, Omega-3 2ziconotide 1pembrolizumab 1nicotinamide-beta-riboside 1glutamic acid diethyl ester 1enfortumab vedotin 1Yoga 1XELOX 1Vitamin D 1Vitamin B Complex 1Vitamin B 6 1Vitamin B 12 1Ultrasonic Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Peripheral Nervous System Diseases × nicotinamide-beta-riboside × Clear all
NCT04112641 2025-07-30

NIAGEN and Persistent Chemotherapy-Induced Peripheral Neuropathy

University of Iowa

Phase 2 Active not recruiting
48 enrolled

Peripheral Nervous System Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡